Page 403 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

CHAPTER 21 ■ Acute Leukemias 387

m . D CBF m x, ( ; )

BOX 21.2 (q ;q ) ( ) ( q / ( , ) ( ;q ), -

AML . T

m j AML m-
New Acute Myeloid Leukemia Subtypes—2016 m -

■ AML RUNX1 m ( ) k m .

■ AML BCR-ABL 1 m ( ) I WHO , m

■ AML CEBPA m ( )(q q . ) ( ; )(q ;q . ) -

■ F m AML/MDS (m ) m GA A

■ N m m q .
m (B % m . P AML NPM ( m )
m AML CEBPA m m

S : F K. CSP 2015 Short Course—Leukemia Classi cation . AML CEBPA m
2016: What, When, “Who,” C S P , S D , AML m m -

CA, . m . T m AML

. AML RUNX m

AML BCR-ABL

-

T F L3 III k . . T k

U , FL x m - BCR-ABL .

m . F L k

k m m Key Laboratory Findings

m m . F L k m %

AML. A m . A m

T CBF m x m x - m m m m k -

m m m m . A k -
, m m m m

k . T m

k m .

BOX 21.3 AML z m ,

, , , m

, m m
New Acute Myeloid Leukemia Criteria m m. A k

. B CEBPA m q AML m mm m

CEBPA m . m k AML. T M:E AML

. R AML-MRC m - .

. M m m m

. I NPM1 m , AML m , x -

NPM1 m ( m ). m m k m m ,

. I CEBPA m , AML , m

CEBPA m ( m ). AML.

. I MDS MDS- I AML, m

, AML-MDS ( . . ).

NPM1, CEBPA m .

. B m

- m . N - PROGNOSIS OF AML

k m ,

m / m MDS. A AML , AML

. A m m % %

m- m : % %

. F m MDS/AML . T m m

. F m m m . O -

m m

. F m MDS/AML - m .

m m , I AML z m m -

F ’ m , — ( ; )(q ;q ); ( ; ) (q ;q ) ( q )—

. I m ,